FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular, to an antibody against the PDGF antigen receptor or to an antigen-binding fragment thereof, as well as a composition containing said receptor and a conjugate. Also disclosed is a drug delivery system containing the above antibody or a fragment thereof.
EFFECT: invention is effective in preventing, alleviating the course of, and treating oncological diseases, as well as for preventing, alleviating the course of, and treating ophthalmic neovascular diseases.
26 cl, 20 dwg, 8 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND METHOD FOR PRODUCTION THEREOF | 2021 |
|
RU2818312C1 |
| ANTIBODY AGAINST THE CELL ADHESION MOLECULE L1 OR ITS ANTIGEN-BINDING FRAGMENT AND CHIMERIC ANTIGEN RECEPTOR CONTAINING IT | 2019 |
|
RU2789360C2 |
| BISPECIFIC PROTEINS AND METHODS OF THEIR PRODUCTION | 2017 |
|
RU2745648C2 |
| FUSION PROTEIN CONTAINING HUMAN LEFTY A PROTEIN VARIANTS AND ITS USE | 2019 |
|
RU2793631C2 |
| ANTIBODIES AGAINST A5 REPRESENTATIVE OF 19 FAMILY WITH SIMILARITY OF SEQUENCES AND THEIR APPLICATION METHOD | 2019 |
|
RU2785436C2 |
| MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO THE THIOREDOXIN-1 EPITOPE, ITS PREPARATION AND APPLICATION | 2018 |
|
RU2791264C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| TRISPECIFIC BINDING MOLECULES FOR TREATING VIRAL HEPATITIS B INFECTION AND BOUND STATES | 2016 |
|
RU2733496C2 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
